Form 4: Cara Therapeutics Director, Susan Shiff, Receives Stock Options and Restricted Stock Units

Director Susan Shiff received stock options and restricted stock units from Cara Therapeutics, according to a recent SEC filing.

Summary

• On June 4, 2024, Susan Shiff, a director of Cara Therapeutics, received 150,647 restricted stock units (RSUs) and stock options for 195,000 shares.
• The RSUs represent the contingent right to receive one share of Cara Therapeutics common stock each.
• The RSUs vest on the earlier of June 4, 2025, or immediately prior to the Issuer's next annual meeting of stockholders following the grant date, subject to continued service as a director.
• The stock options have an exercise price of $0.664 and also vest on the earlier of June 4, 2025, or immediately prior to the Issuer's next annual meeting of stockholders following the grant date, subject to continued service as a director.
• Following these transactions, Shiff directly owns 202,085 shares of Cara Therapeutics common stock and holds options for 195,000 shares.

Sentiment

Score: 7

Explanation: The sentiment is neutral to slightly positive. It reflects standard director compensation practices, aligning director interests with shareholders. There are no explicit negative implications.

Positives

• The grant of RSUs and stock options to a director aligns their interests with those of the shareholders.
• The vesting schedule incentivizes continued service as a director.

Future Outlook

The document does not contain specific forward-looking statements beyond the vesting schedule of the granted securities.

Industry Context

This type of equity grant is a common practice for compensating directors of publicly traded companies, aligning their interests with shareholders and incentivizing long-term value creation.

Comparison to Industry Standards

• Equity compensation for board members is a standard practice across the pharmaceutical and biotechnology industries.
• Companies like Amgen, Gilead Sciences, and Biogen also use a mix of stock options and restricted stock units to compensate their directors.
• The specific amounts and vesting schedules vary based on company size, performance, and industry benchmarks.

Stakeholder Impact

• The grant of equity to a director can positively impact shareholders by aligning the director's interests with the company's long-term success.
• Employees may view this as a positive sign of the company's commitment to its leadership.

Key Dates